CLL Society Joins Advocates in Warning CMS that “Monitoring” Health Plans’ Efforts to Delay/Deny Needed Prescriptions is Not Enough

CLL Society joins a growing number of patient advocacy organizations interested in ensuring that the benefits of the recently passed Inflation Reduction Act are not outweighed by the components that cause us concern. We are thrilled that the newly minted out-of-pocket cap on patient spending will likely be transformative in limiting patients’ expenses. More than one study has indicated savings, especially for cancer patients. However, the same law shifts more of the costs to health plans, which increases our fear that those health plans will more aggressively “manage” patients’ ability to get the medications they need.
CLL Society will continue to closely watch for health plan changes that suggest cost saving measures at our patients’ expense. The tradeoff for lower out of pocket costs cannot be denials or delays in the medications we need.

Download the letter here.